Verition Fund Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-29,100
Closed -$1.21M 3570
2024
Q4
$1.21M Sell
29,100
-2,600
-8% -$124K ﹤0.01% 1921
2024
Q3
$2.12M Hold
31,700
0.01% 1378
2024
Q2
$3.76M Buy
31,700
+18,800
+146% +$2.38M 0.02% 892
2024
Q1
$1.37M Buy
+12,900
New +$1.3M 0.01% 1445

Other funds holding MRNA

Verition Fund Management's MRNA Position: Q1 2026 in Review

Verition Fund Management sold out of Moderna (MRNA) in Q1 2026, closing a stake of 452,529 shares — an estimated $13.3M sold.

Verition Fund Management first reported a position in MRNA in Q2 2020 and held it in 20 quarters. The position peaked at $13.3M in Q4 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Verition Fund Management reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 452,529 Moderna shares in Q1 2026, an estimated $13.3M.
  • Verition Fund Management first reported a position in Moderna in Q2 2020 and held it in 20 quarters.
  • Verition Fund Management's Moderna position peaked at $13.3M in Q4 2025.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.